GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shanghai Haohai Biological Technology Co Ltd (HKSE:06826) » Definitions » EBIT

Shanghai Haohai Biological Technology Co (HKSE:06826) EBIT : HK$564 Mil (TTM As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Shanghai Haohai Biological Technology Co EBIT?

Shanghai Haohai Biological Technology Co's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was HK$127 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was HK$564 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Shanghai Haohai Biological Technology Co's annualized ROC % for the quarter that ended in Mar. 2024 was 8.04%. Shanghai Haohai Biological Technology Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 24.15%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Shanghai Haohai Biological Technology Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 4.38%.


Shanghai Haohai Biological Technology Co EBIT Historical Data

The historical data trend for Shanghai Haohai Biological Technology Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Haohai Biological Technology Co EBIT Chart

Shanghai Haohai Biological Technology Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 488.37 310.50 474.62 271.73 563.90

Shanghai Haohai Biological Technology Co Quarterly Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 128.87 153.48 150.65 133.05 126.92

Competitive Comparison of Shanghai Haohai Biological Technology Co's EBIT

For the Biotechnology subindustry, Shanghai Haohai Biological Technology Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shanghai Haohai Biological Technology Co's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Shanghai Haohai Biological Technology Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Shanghai Haohai Biological Technology Co's EV-to-EBIT falls into.



Shanghai Haohai Biological Technology Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$564 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shanghai Haohai Biological Technology Co  (HKSE:06826) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Shanghai Haohai Biological Technology Co's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

ROC % (Q: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Mar. 2024 ))/ count )
=438.972 * ( 1 - 18.99% )/( (4410.79 + 4432.872)/ 2 )
=355.6112172/4421.831
=8.04 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=7771.843 - 351.978 - ( 3009.075 - max(0, 783.092 - 4101.828+3009.075))
=4410.79

Invested Capital(Q: Mar. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=7813.715 - 418.857 - ( 2961.986 - max(0, 749.293 - 4068.562+2961.986))
=4432.872

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Shanghai Haohai Biological Technology Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=507.672/( ( (1698.685 + max(512.091, 0)) + (1657.363 + max(336.516, 0)) )/ 2 )
=507.672/( ( 2210.776 + 1993.879 )/ 2 )
=507.672/2102.3275
=24.15 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(358.607 + 575.518 + 124.118) - (351.978 + 0 + 194.174)
=512.091

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(357.13 + 579.696 + 138.12) - (418.857 + 0 + 319.573)
=336.516

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Shanghai Haohai Biological Technology Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2024 )
=564.104/12885.190
=4.38 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shanghai Haohai Biological Technology Co EBIT Related Terms

Thank you for viewing the detailed overview of Shanghai Haohai Biological Technology Co's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Shanghai Haohai Biological Technology Co (HKSE:06826) Business Description

Traded in Other Exchanges
Address
No. 1386 Hongqiao Road, 23rd Floor, WenGuang Plaza, Changning District, Shanghai, CHN
Shanghai Haohai Biological Technology Co Ltd is engaged in the manufacturing and sale of biologicals, medical hyaluronate, and ophthalmology products. It is also engaged in the research and development of biological engineering, pharmaceutical and ophthalmology products, and the provision of related services. Its products are categorized into four types comprising ophthalmology, medical aesthetics, orthopedics, and anti-adhesion. Geographically, it has operations in Mainland China which is the key revenue driver, the United States, the United Kingdom, and other countries.
Executives
Morgan Stanley 2201 Interest of corporation controlled by you
Dalton Investments Llc 2102 Investment manager
The Bank Of New York Mellon Corporation 2201 Interest of corporation controlled by you
Templeton Investment Counsel, Llc 2102 Investment manager
Kabouter Management Llc 2102 Investment manager
Royal Bank Of Canada 2201 Interest of corporation controlled by you
Kabouter International Insight Fund, Llc 2102 Investment manager
Prudence Investment Management (hong Kong) Limited 2102 Investment manager

Shanghai Haohai Biological Technology Co (HKSE:06826) Headlines

No Headlines